At a glance
The Clorox Company is worth $10.89B, about 14 times its fiscal 2025 earnings. Revenue grew 0.2% to $7.10B in fiscal 2025, with 11.4% kept as profit; over 5 years it has grown 1.1% a year. It pays a 5.54% dividend yield, raised every year for at least 3 years, and returned $4.17B to shareholders in dividends and buybacks over FY2021–FY2025. The stock returned −16.0% over the past year with dividends reinvested and −8.2% a year over five years, against +11.5% and +11.7% for the S&P 500. At its worst it fell 14.0% in the 2020 crash (S&P 500: 33.7%) and 33.4% in the 2022 bear market (S&P 500: 24.5%), and was back at its earlier high 1 month and 30 months after the lows.
The business in plain English
Clorox makes everyday consumer products, led by cleaning and disinfecting goods. Besides its namesake Clorox line, it owns Pine-Sol and Formula 409 cleaners, Liquid-Plumr clog removers, Glad trash bags and wraps, Fresh Step cat litter, Kingsford grilling products, Hidden Valley dressings, Brita water filters and Burt's Bees natural personal care. The company says more than 80% of its sales come from brands ranked No. 1 or No. 2 in their categories. Net sales were $6.72 billion in the fiscal year (Clorox's business year) that ended June 30, 2026.
Most sales go to retailers, including mass merchants, grocery stores, warehouse clubs, dollar stores and e-commerce sites, which resell to households. Gross margin, the share of sales left after production costs, was 42.3% in fiscal 2026. Clorox also sells to businesses under the CloroxPro and Clorox Healthcare names. In April 2026 it bought GOJO Industries, maker of Purell. The deal added healthcare and institutional customers and a large installed base of dispensers that drives repeat orders.
Clorox reports four segments. Health and Wellness, its U.S. cleaning, disinfecting and professional business, brought in 40.1% of fiscal 2026 sales. Household (Glad, cat litter and Kingsford) made up 26.6%. Lifestyle (Hidden Valley, Brita and Burt's Bees) made up 16.7%, and International 16.6%. Overall, about 84% of sales came from the United States.
Price history
The interactive chart needs JavaScript.
CLX -16.0% over the year to Nov 2, 2026, total return with dividends reinvested.
How it makes money
By business segment
| Health and Wellness | $2.70B | |
| Household | $1.79B | |
| Lifestyle | $1.12B | |
| International | $1.11B |
By geography
| United States | $5.63B | |
| Foreign | $1.09B |
Latest results
- In Q4 FY2026 (ended Sep 30, 2026), revenue was $1.91B, up 33.3% from a year earlier, and net income was $170.0M (+112.5%).
- For fiscal 2025, revenue was $7.10B (+0.2% year over year; +1.1% a year from FY2020 to FY2025) with a 11.4% net margin.
Financial health check
| Revenue growth a year (FY2020–FY2025) | +1.1% watch |
|---|---|
| Free cash flow margin | 10.7% good |
| Return on equity (FY2025) | 252.3% (lifted by a small equity base, often the result of years of buybacks) good |
| Return on assets (FY2025) | 14.6% good |
| Net cash (cash minus debt) | $-4.97B weak |
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2020 | $6.72B | $939.0M | $1.29B |
| FY2021 | $7.34B | $710.0M | $945.0M |
| FY2022 | $7.11B | $462.0M | $535.0M |
| FY2023 | $7.39B | $149.0M | $930.0M |
| FY2024 | $7.09B | $280.0M | $483.0M |
| FY2025 | $7.10B | $810.0M | $761.0M |
Valuation snapshot
| Market value | $10.89B |
|---|---|
| P/E ratio | 13.8 |
| Dividend yield | 5.54% |
Rank among 1514 US companies
Market value at each year end
The Clorox’s market value went from $15.45B at the end of 2016 to $10.89B on Nov 2, 2026, down 30%; since the end of 2025 it is down 11%.
Show as a table
| Year end | Market value | Change |
|---|---|---|
| Nov 2, 2026 | $10.89B | -11.4% |
| 2025 | $12.30B | -38.8% |
| 2024 | $20.10B | +13.6% |
| 2023 | $17.69B | +2.2% |
| 2022 | $17.31B | -19.2% |
| 2021 | $21.42B | -15.8% |
| 2020 | $25.45B | +32.1% |
| 2019 | $19.27B | -2.1% |
| 2018 | $19.68B | +2.6% |
| 2017 | $19.18B | +24.1% |
| 2016 | $15.45B |
Price behavior
| YTD | 1 yr | 3 yr | 5 yr | 10 yr | |
|---|---|---|---|---|---|
| CLX price data to Nov 2, 2026 | -6.3% | -16.0% | -6.3% | -8.2% | +0.6% |
Show as a table
| Year | Price data |
|---|---|
| 2026 (to date) | -6.3% |
| 2025 | -35.6% |
| 2024 | +17.7% |
| 2023 | +5.0% |
| 2022 | -17.0% |
| 2021 | -11.5% |
| 2020 | +34.5% |
| 2019 | +2.2% |
| 2018 | +6.5% |
| 2017 | +27.1% |
| 2016 | -3.0% |
| 2015 | +25.0% |
| 2014 | +15.9% |
| 2013 | +30.8% |
| 2012 | +13.9% |
| 2011 | +8.8% |
| 2010 | +7.2% |
| 2009 | +13.7% |
| 2008 | -12.1% |
| 2007 | +3.9% |
| 2006 | +14.9% |
| 2008 financial crisis stocks fell Oct 9, 2007 – Mar 9, 2009 | Lost 22.9% over that stretch · deepest drop along the way 28.4%, back to its old high 9.1 months after the low |
|---|---|
| 2020 COVID crash stocks fell Feb 19, 2020 – Mar 23, 2020 | Gained 3.2% over that stretch · deepest drop along the way 14%, back to its old high 1.4 months after the low |
| 2022 bear market stocks fell Jan 3, 2022 – Oct 12, 2022 | Lost 24.5% over that stretch · deepest drop along the way 33.4%, back to its old high 29.7 months after the low |
Insider activity
Form 4 filings from 2025-11-03 to 2026-11-03 (25 read): 0 open-market purchases and 0 sales ($0.00).
Who owns it
Large shareholders (13G filings)
| Vanguard Capital Management | 7.35% | Mar 31, 2026 |
| BlackRock, Inc. | 6.3% | Sep 30, 2026 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 0.9% | Dec 31, 2024 |
ETFs with the most weight in CLX
| ERNZ TrueShares Active Yield ETF | 3.62% |
| ACSI American Customer Satisfaction ETF | 2.71% |
| FDIV MarketDesk Focused U.S. Dividend ETF | 2.15% |
| VSDA VictoryShares Dividend Accelerator ETF | 1.51% |
| NOBL ProShares S&P 500 Dividend Aristocrats ETF | 1.39% |
| KNG FT Vest S&P 500 Dividend Aristocrats Target Income ETF | 1.33% |
| MGRO VanEck Morningstar Wide Moat Growth ETF | 1.07% |
| SDY SPDR S&P Dividend ETF | 1.02% |
What could go wrong
- Purell deal has to pay off. Clorox bought GOJO, maker of Purell, in April 2026 to grow in healthcare and institutional sales. Its annual report flags the deal as carrying risks. Weak integration or demand would undercut expected growth.
- New business software still settling in. Clorox finished switching to a new enterprise resource planning (ERP) system, the software running orders and supply, in fiscal 2026, part of a roughly $580 million overhaul. It disrupted sales; payoffs are expected long-term.
- Retailer orders can swing sales. In fiscal 2026, about 84% of sales came from the U.S., mostly through retailers. When retailers stocked up before the ERP switch and then drew down inventory, fiscal 2026 sales took the hit.
- Heavy debt, almost no equity cushion. As of June 30, 2026, Clorox had about $5.1 billion of debt, $143 million of cash and just $90 million of shareholders' equity (assets minus liabilities). That leaves less room to absorb another weak year.
- Dividend now exceeds earnings and cash flow. Fiscal 2026 dividends equaled about 103% of earnings and 149% of free cash flow, the cash left after capital spending. Without a profit recovery, future raises could stay tiny or stop.
- Softer spending and higher costs. Economic uncertainty slowed demand in Clorox's categories in fiscal 2026 while manufacturing and logistics costs rose. Net sales fell 5.4% and diluted earnings per share dropped 26%. A longer slowdown would keep pressure on profits.
Recent events
- Quarterly results released; Investor presentation or announcement
- Executive or board change; Investor presentation or announcement
- Quarterly results released; Investor presentation or announcement
- Executive or board change; Investor presentation or announcement
- Executive or board change; Investor presentation or announcement
- Other company announcement
- Quarterly results released; Investor presentation or announcement
- Investor presentation or announcement; Other company announcement
- Major agreement signed; New debt or financial obligation
- Quarterly results released; Investor presentation or announcement
For income and retirement investors
Clorox pays a sizable dividend: the yield was 5.73% as of October 28, 2026, helped by a falling share price. Its annual report describes a longstanding practice of annual increases, but the July 2026 raise was 1%, and per-share dividends grew only about 2% a year from fiscal 2021 to fiscal 2026, reaching $4.96. Fiscal 2026 dividends equaled about 103% of earnings and 149% of free cash flow, the cash left after capital spending. Buybacks totaled $613 million over fiscal 2022–2026, against $2.95 billion of dividends; the share count fell 1.5% over five years.
Its record in past downturns is mixed. During the 2008 financial crisis the shares fell 28.4% at worst and regained their high about nine months after the March 2009 low. While the market crashed in early 2020, Clorox shares rose 3.2%. In the 2022 bear market they fell 33.4% and needed nearly 30 months to recover. Single stocks carry more risk than diversified funds.
Questions investors ask
How does Clorox make money?
Clorox makes money by selling branded household and professional products, mostly through retailers such as mass merchants, grocery stores, warehouse clubs, dollar stores and e-commerce sites. Its brands include Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, Burt's Bees and, since April 2026, Purell. Net sales were $6.72 billion in fiscal 2026, which ended June 30, 2026. The Health and Wellness segment produced 40.1% of sales, and about 84% came from the United States.
Does Clorox raise its dividend every year?
The company says it does. In July 2026 Clorox announced a 1% dividend increase, which its annual report calls consistent with a longstanding practice of annual raises. The increases have been modest: dividends per share grew about 2% a year from fiscal 2021 to fiscal 2026, reaching $4.96. Clorox paid $602 million in dividends in fiscal 2026. The yield was 5.73% as of October 28, 2026, lifted partly by the falling share price.
Can Clorox afford its dividend?
Not from fiscal 2026 results alone. Dividends of $4.96 per share exceeded diluted earnings of $4.81 per share, a payout of about 103%. Free cash flow, the cash left after capital spending, was $405 million against $602 million of dividends paid, about 149%. In fiscal 2025, by contrast, free cash flow of $761 million covered dividends. The company also carried about $5.1 billion of debt as of June 30, 2026, so a lasting gap would be hard to fund.
Why has Clorox stock fallen?
The drop has tracked weaker results. Clorox shares fell 20.8% in the year to October 28, 2026, after a 35.6% fall in calendar 2025. In fiscal 2026, net sales fell 5.4% as shoppers pulled back and retailers drew down stock they had bought ahead of Clorox's software switch. Diluted earnings per share fell 26%, also hurt by higher manufacturing and logistics costs. As of October 28, 2026, the shares traded at about 18 times fiscal 2026 earnings.
Does Clorox own Purell?
Yes. Clorox completed its purchase of GOJO Industries, the maker of Purell, in April 2026. GOJO now operates as Clorox Purell, based in northeast Ohio. The deal expands Clorox in health and hygiene and in business-to-business sales to healthcare and other institutions, where a large installed base of dispensing systems drives recurring demand. Purell sits in the Health and Wellness segment. The acquisition's long-term payoff is not yet proven, and the company's filings flag it as carrying risks.